Jamie Doggett

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Several clinicians expressed concern about inhaler costs for those with COPD in January. AstraZeneca, Boehringer Ingelheim and GSK agreed to cap the price of their inhaler products at $35 in March.

You've successfully added COPD to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: The rise in discussion of ventilation support was due to two articles published in the June issue of CHEST being shared. Many of the posts on COPD medications focused on the NOTUS trial results.

In a recent study of the social media conversations of healthcare professionals (HCPs) in Europe using CREATION Pinpoint, it was discovered that since the COVID-19 pandemic, the overall level of interest in antimicrobial resistance (AMR) has waned. After an initial explosion of online conversations among HCPs about COVID-19 in spring 2020 (see Figure 1), the level has been slowly declining.